VIRX Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 10.69%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Viracta Therapeutics Share Price & Price History
Current Price: $0.01
Price Change: +0.30 (1.20%)
As of 07/25/2025 01:00 AM ET
Viracta Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/27/2024 | Daniel R. Chevallard | CFO | Sell | 3,405 | $0.73 | $2,485.65 | 102,306 |  |
| 11/30/2023 | Mark Rothera | CEO | Buy | 52,094 | $0.49 | $25,526.06 | 52,094 | |
| 11/28/2023 | Daniel R. Chevallard | CFO | Sell | 3,720 | $0.50 | $1,860.00 | 98,822 | |
| 8/28/2023 | Daniel R. Chevallard | CFO | Sell | 3,512 | $1.45 | $5,092.40 | 95,653 | |
| 5/25/2023 | Daniel R. Chevallard | CFO | Sell | 3,635 | $1.42 | $5,161.70 | 92,277 | |
| 2/27/2023 | Daniel R. Chevallard | CFO | Sell | 3,599 | $1.68 | $6,046.32 | 89,023 | |
| 2/27/2023 | Lisa Rojkjaer | Insider | Sell | 2,156 | $1.68 | $3,622.08 | 48,087 | |
Viracta Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/14/2024 | Stonepine Capital Management LLC | 500,000 | $0.12M | 0.1% | N/A | 1.268% |  |
| 11/13/2023 | Acadian Asset Management LLC | 97,109 | $99K | 0.0% | -42.1% | 0.252% | |
| 8/7/2023 | Acadian Asset Management LLC | 167,818 | $0.24M | 0.0% | +74.6% | 0.436% | |
| 8/2/2023 | MAI Capital Management | 307,570 | $0.43M | 0.0% | -18.9% | 0.800% | |
| 7/20/2023 | Bailard Inc. | 47,700 | $67K | 0.0% | +139.7% | 0.124% | |
| 5/15/2023 | Rubric Capital Management LP | 1,487,385 | $2.37M | 0.1% | +11.8% | 3.872% | |
| 5/10/2023 | MAI Capital Management | 379,468 | $0.60M | 0.0% | -11.1% | 0.988% | |
| 5/8/2023 | Bailard Inc. | 19,900 | $32K | 0.0% | N/A | 0.052% | |
| 4/4/2023 | Trust Co. of Toledo NA OH | 28,000 | $45K | 0.0% | N/A | 0.073% | |
| 2/9/2023 | MAI Capital Management | 426,916 | $0.62M | 0.0% | -33.0% | 1.118% | |
| 11/14/2022 | Ergoteles LLC | 132,636 | $0.57M | 0.0% | -14.7% | 0.353% | |
| 11/14/2022 | Rubric Capital Management LP | 994,801 | $4.25M | 0.2% | N/A | 2.649% | |
| 11/8/2022 | Hamilton Lane Advisors LLC | 35,791 | $0.15M | 0.1% | -49.9% | 0.095% | |
| 8/15/2022 | Laurion Capital Management LP | 698,000 | $2.71M | 0.0% | N/A | 1.858% | |
| 8/12/2022 | Ensign Peak Advisors Inc | 63,406 | $0.25M | 0.0% | +4.8% | 0.169% | |
| 7/20/2022 | Clear Harbor Asset Management LLC | 25,000 | $97K | 0.0% | N/A | 0.067% | |
| 7/19/2022 | MAI Capital Management | 647,950 | $2.51M | 0.0% | +70.2% | 1.728% | |
| 5/11/2022 | Veritable L.P. | 24,836 | $0.12M | 0.0% | N/A | 0.066% | |
| 5/10/2022 | MAI Capital Management | 380,788 | $1.81M | 0.0% | N/A | 1.016% | |
| 2/25/2022 | AlphaCentric Advisors LLC | 90,000 | $0.33M | 0.1% | N/A | 0.241% | |
| 2/11/2022 | Ensign Peak Advisors Inc | 60,515 | $0.22M | 0.0% | N/A | 0.162% | |
| 2/8/2022 | ProShare Advisors LLC | 13,174 | $49K | 0.0% | N/A | 0.035% | |
| 2/8/2022 | Northern Trust Corp | 293,492 | $1.07M | 0.0% | -2.8% | 0.787% | |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 73,011 | $0.27M | 0.0% | N/A | 0.196% | |
| 11/16/2021 | Janus Henderson Group PLC | 249,686 | $2M | 0.0% | -20.4% | 0.669% | |
| 11/16/2021 | Metropolitan Life Insurance Co NY | 5,766 | $46K | 0.0% | -48.8% | 0.015% | |
| 11/15/2021 | Royal Bank of Canada | 182,319 | $1.46M | 0.0% | -6.3% | 0.490% | |
| 11/15/2021 | Franklin Resources Inc. | 43,618 | $0.35M | 0.0% | N/A | 0.117% | |
| 11/15/2021 | Jasper Ridge Partners L.P. | 92,939 | $0.75M | 0.0% | N/A | 0.250% | |
| 11/12/2021 | Jump Financial LLC | 21,852 | $0.18M | 0.0% | N/A | 0.059% | |
| 11/12/2021 | Oppenheimer & Co. Inc. | 38,037 | $0.31M | 0.0% | N/A | 0.102% | |
| 11/12/2021 | Geode Capital Management LLC | 481,301 | $3.86M | 0.0% | +7.1% | 1.293% | |
| 11/10/2021 | Goldman Sachs Group Inc. | 171,194 | $1.37M | 0.0% | -34.5% | 0.460% | |
| 11/10/2021 | Citigroup Inc. | 4,206 | $34K | 0.0% | +109.6% | 0.011% | |
| 11/9/2021 | Bourgeon Capital Management LLC | 18,750 | $0.15M | 0.0% | +3,650.0% | 0.050% | |
| 11/9/2021 | BlackRock Inc. | 2,085,048 | $16.72M | 0.0% | +1.2% | 5.600% | |
| 11/8/2021 | State Board of Administration of Florida Retirement System | 10,068 | $81K | 0.0% | N/A | 0.027% | |
| 11/5/2021 | Advisor Group Holdings Inc. | 4,999 | $39K | 0.0% | N/A | 0.013% | |
| 11/2/2021 | New York State Common Retirement Fund | 22,055 | $0.18M | 0.0% | -28.9% | 0.059% | |
| 11/1/2021 | SG Americas Securities LLC | 20,454 | $0.16M | 0.0% | N/A | 0.055% | |
| 10/22/2021 | Spire Wealth Management | 3,698 | $30K | 0.0% | -48.1% | 0.010% | |
Data available starting January 2016
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Read More on Viracta Therapeutics
Volume
N/A
Average Volume
1,111,440 shs
Market Capitalization
$388.70 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.06
Who are the company insiders with the largest holdings of Viracta Therapeutics?
